Skip to main content
Top
Published in: BMC Cancer 1/2005

Open Access 01-12-2005 | Research article

Modeling the effect of age in T1-2 breast cancer using the SEER database

Authors: Patricia Tai, Gábor Cserni, Jan Van De Steene, Georges Vlastos, Mia Voordeckers, Melanie Royce, Sang-Joon Lee, Vincent Vinh-Hung, Guy Storme

Published in: BMC Cancer | Issue 1/2005

Login to get access

Abstract

Background

Modeling the relationship between age and mortality for breast cancer patients may have important prognostic and therapeutic implications.

Methods

Data from 9 registries of the Surveillance, Epidemiology, and End Results Program (SEER) of the United States were used. This study employed proportional hazards to model mortality in women with T1-2 breast cancers. The residuals of the model were used to examine the effect of age on mortality. This procedure was applied to node-negative (N0) and node-positive (N+) patients. All causes mortality and breast cancer specific mortality were evaluated.

Results

The relationship between age and mortality is biphasic. For both N0 and N+ patients among the T1-2 group, the analysis suggested two age components. One component is linear and corresponds to a natural increase of mortality with each year of age. The other component is quasi-quadratic and is centered around age 50. This component contributes to an increased risk of mortality as age increases beyond 50. It suggests a hormonally related process: the farther from menopause in either direction, the more prognosis is adversely influenced by the quasi-quadratic component. There is a complex relationship between hormone receptor status and other prognostic factors, like age.

Conclusion

The present analysis confirms the findings of many epidemiological and clinical trials that the relationship between age and mortality is biphasic. Compared with older patients, young women experience an abnormally high risk of death. Among elderly patients, the risk of death from breast cancer does not decrease with increasing age. These facts are important in the discussion of options for adjuvant treatment with breast cancer patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fodor J, Polgar C, Major T, Nemeth G: Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size. Strahlenther Onkol. 2003, 179: 197-202. 10.1007/s00066-003-1010-7.CrossRefPubMed Fodor J, Polgar C, Major T, Nemeth G: Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size. Strahlenther Onkol. 2003, 179: 197-202. 10.1007/s00066-003-1010-7.CrossRefPubMed
2.
go back to reference Freedman GM, Fowble BL, Hanlon AL, Myint MA, Hoffman JP, Sigurdson ER, Eisenberg BL, Goldstein LJ, Fein DA: A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. Int J Radiat Oncol Biol Phys. 1998, 41: 599-605. 10.1016/S0360-3016(98)00103-5.CrossRefPubMed Freedman GM, Fowble BL, Hanlon AL, Myint MA, Hoffman JP, Sigurdson ER, Eisenberg BL, Goldstein LJ, Fein DA: A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. Int J Radiat Oncol Biol Phys. 1998, 41: 599-605. 10.1016/S0360-3016(98)00103-5.CrossRefPubMed
3.
go back to reference Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M: Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ. 2000, 320: 474-478. 10.1136/bmj.320.7233.474.CrossRefPubMedPubMedCentral Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M: Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ. 2000, 320: 474-478. 10.1136/bmj.320.7233.474.CrossRefPubMedPubMedCentral
4.
go back to reference Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L, Cancer and Leukemia Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004, 351: 971-977. 10.1056/NEJMoa040587.CrossRefPubMed Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L, Cancer and Leukemia Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004, 351: 971-977. 10.1056/NEJMoa040587.CrossRefPubMed
5.
go back to reference Kunkler I, Williams L, Prescott R, King C: Re: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004, 96: 1255-CrossRefPubMed Kunkler I, Williams L, Prescott R, King C: Re: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004, 96: 1255-CrossRefPubMed
6.
go back to reference Vinh-Hung V, Verschraegen C, Royce M, Van de Steene J, Tai P, Cserni G, Storme G, Vlastos G: Response: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004, 96: 1255-1257.CrossRef Vinh-Hung V, Verschraegen C, Royce M, Van de Steene J, Tai P, Cserni G, Storme G, Vlastos G: Response: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004, 96: 1255-1257.CrossRef
7.
go back to reference National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973–1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April based on the November 2001 submission. 2002, National Cancer Institute, Bethesda, MD, [http://seer.cancer.gov] National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973–1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April based on the November 2001 submission. 2002, National Cancer Institute, Bethesda, MD, [http://​seer.​cancer.​gov]
8.
go back to reference Therneau TM, Grambsch PM: Modeling survival data: extending the Cox model. 2000, New York, NY, Springer-Verlag, 87-152. Therneau TM, Grambsch PM: Modeling survival data: extending the Cox model. 2000, New York, NY, Springer-Verlag, 87-152.
9.
go back to reference Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994, 81: 515-526.CrossRef Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994, 81: 515-526.CrossRef
10.
go back to reference Vinh-Hung V, Burzykowski T, Cserni G, Voordeckers M, Van De Steene J, Storme G: Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol. 2003, 22: 697-704.PubMed Vinh-Hung V, Burzykowski T, Cserni G, Voordeckers M, Van De Steene J, Storme G: Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol. 2003, 22: 697-704.PubMed
11.
go back to reference Verschraegen C, Vinh-Hung V, Cserni G, Gordon R, Royce ME, Vlastos G, Tai P, Storme G: Modeling the effect of tumor size in early breast cancer. Ann Surg. 2005, 241: 309-318. 10.1097/01.sla.0000150245.45558.a9.CrossRefPubMedPubMedCentral Verschraegen C, Vinh-Hung V, Cserni G, Gordon R, Royce ME, Vlastos G, Tai P, Storme G: Modeling the effect of tumor size in early breast cancer. Ann Surg. 2005, 241: 309-318. 10.1097/01.sla.0000150245.45558.a9.CrossRefPubMedPubMedCentral
12.
go back to reference Vinh-Hung V, Gordon R: Quantitative target sizes for breast tumor detection prior to metastasis: a prerequisite to rational design of 4D scanners for breast screening. Technol Cancer Res Treat. 2005, 4: 11-21.CrossRefPubMed Vinh-Hung V, Gordon R: Quantitative target sizes for breast tumor detection prior to metastasis: a prerequisite to rational design of 4D scanners for breast screening. Technol Cancer Res Treat. 2005, 4: 11-21.CrossRefPubMed
13.
go back to reference Vinh-Hung V, Burzykowski T, Van de Steene J, Storme G, Soete G: Post-surgery radiation in early breast cancer: survival analysis of registry data. Radiother Oncol. 2002, 64: 281-290. 10.1016/S0167-8140(02)00105-6.CrossRefPubMed Vinh-Hung V, Burzykowski T, Van de Steene J, Storme G, Soete G: Post-surgery radiation in early breast cancer: survival analysis of registry data. Radiother Oncol. 2002, 64: 281-290. 10.1016/S0167-8140(02)00105-6.CrossRefPubMed
14.
go back to reference Sauerbrei W, Royston P: Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J Roy Stat Soc A Sta. 1999, 162 (Part 1): 71-94. 10.1111/1467-985X.00122.CrossRef Sauerbrei W, Royston P: Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J Roy Stat Soc A Sta. 1999, 162 (Part 1): 71-94. 10.1111/1467-985X.00122.CrossRef
15.
go back to reference Bryant J, Fisher B, Gunduz N, Costantino JP, Emir B: S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 1998, 51: 239-253. 10.1023/A:1006184428857.CrossRefPubMed Bryant J, Fisher B, Gunduz N, Costantino JP, Emir B: S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 1998, 51: 239-253. 10.1023/A:1006184428857.CrossRefPubMed
16.
go back to reference Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M: Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer. 1999, 79: 1752-1760. 10.1038/sj.bjc.6690279.CrossRefPubMedPubMedCentral Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M: Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer. 1999, 79: 1752-1760. 10.1038/sj.bjc.6690279.CrossRefPubMedPubMedCentral
17.
go back to reference Adami HO, Malker B, Holmberg L, Persson I, Stone B: The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986, 315: 559-563.CrossRefPubMed Adami HO, Malker B, Holmberg L, Persson I, Stone B: The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986, 315: 559-563.CrossRefPubMed
18.
go back to reference Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N: Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer. 2001, 91: 1679-1687. 10.1002/1097-0142(20010415)91:8+<1679::AID-CNCR1183>3.0.CO;2-8.CrossRefPubMed Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N: Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer. 2001, 91: 1679-1687. 10.1002/1097-0142(20010415)91:8+<1679::AID-CNCR1183>3.0.CO;2-8.CrossRefPubMed
19.
go back to reference Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A: Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet. 2000, 355: 1869-1874. 10.1016/S0140-6736(00)02292-3.CrossRefPubMed Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A: Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet. 2000, 355: 1869-1874. 10.1016/S0140-6736(00)02292-3.CrossRefPubMed
21.
go back to reference Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY: Do young breast cancer patients have worse outcomes?. J Surg Res. 2003, 113: 109-113. 10.1016/S0022-4804(03)00179-3.CrossRefPubMed Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY: Do young breast cancer patients have worse outcomes?. J Surg Res. 2003, 113: 109-113. 10.1016/S0022-4804(03)00179-3.CrossRefPubMed
22.
go back to reference Rapiti E, Fioretta G, Verkooijen HM, Vlastos G, Schafer P, Sappino AP, Kurtz J, Neyroud-Caspar I, Bouchardy C: Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer. 2005, 41: 1446-1452. 10.1016/j.ejca.2005.02.029.CrossRefPubMed Rapiti E, Fioretta G, Verkooijen HM, Vlastos G, Schafer P, Sappino AP, Kurtz J, Neyroud-Caspar I, Bouchardy C: Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer. 2005, 41: 1446-1452. 10.1016/j.ejca.2005.02.029.CrossRefPubMed
23.
go back to reference Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Kurtz J, Sappino AP, Vlastos G: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003, 21: 3580-3587. 10.1200/JCO.2003.02.046.CrossRefPubMed Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Kurtz J, Sappino AP, Vlastos G: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003, 21: 3580-3587. 10.1200/JCO.2003.02.046.CrossRefPubMed
24.
go back to reference Lash TL, Silliman RA, Guadagnoli E, Mor V: The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer. 2000, 89: 1739-1747. 10.1002/1097-0142(20001015)89:8<1739::AID-CNCR14>3.0.CO;2-F.CrossRefPubMed Lash TL, Silliman RA, Guadagnoli E, Mor V: The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer. 2000, 89: 1739-1747. 10.1002/1097-0142(20001015)89:8<1739::AID-CNCR14>3.0.CO;2-F.CrossRefPubMed
25.
go back to reference Truong PT, Lee J, Kader HA, Speers CH, Olivotto IA: Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy. Eur J Cancer. 2005, 41: 1267-1277. 10.1016/j.ejca.2005.02.027.CrossRefPubMed Truong PT, Lee J, Kader HA, Speers CH, Olivotto IA: Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy. Eur J Cancer. 2005, 41: 1267-1277. 10.1016/j.ejca.2005.02.027.CrossRefPubMed
26.
go back to reference Vinh-Hung V, Verschraegen C, Royce M, Van de Steene J, Tai P, Cserni G, Storme G, Vlastos G: Re: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004, 96: 1255-1257.CrossRef Vinh-Hung V, Verschraegen C, Royce M, Van de Steene J, Tai P, Cserni G, Storme G, Vlastos G: Re: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004, 96: 1255-1257.CrossRef
Metadata
Title
Modeling the effect of age in T1-2 breast cancer using the SEER database
Authors
Patricia Tai
Gábor Cserni
Jan Van De Steene
Georges Vlastos
Mia Voordeckers
Melanie Royce
Sang-Joon Lee
Vincent Vinh-Hung
Guy Storme
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2005
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-5-130

Other articles of this Issue 1/2005

BMC Cancer 1/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine